Xiao Y, Sun J, Liu M, Wang H, Guan J
BMC Nurs. 2025; 24(1):119.
PMID: 39901243
PMC: 11789319.
DOI: 10.1186/s12912-025-02769-8.
Bejrananda T, Takahara K, Sowanthip D, Motonaga T, Yagi K, Nakamura W
Sci Rep. 2023; 13(1):15835.
PMID: 37740045
PMC: 10517009.
DOI: 10.1038/s41598-023-43092-z.
Neris R, Nascimento L, Zago M
Support Care Cancer. 2022; 30(4):3485-3494.
PMID: 35015135
DOI: 10.1007/s00520-021-06786-6.
El-Haouly A, Lacasse A, El-Rami H, Liandier F, Dragomir A
Curr Oncol. 2021; 28(1):26-39.
PMID: 33704114
PMC: 7816191.
DOI: 10.3390/curroncol28010005.
Groarke A, Curtis R, Skelton J, Groarke J
PLoS One. 2020; 15(9):e0239469.
PMID: 32941547
PMC: 7498057.
DOI: 10.1371/journal.pone.0239469.
Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index.
Osawa T, Wei J, Abe T, Honda M, Yamada S, Furumido J
Int J Clin Oncol. 2020; 25(12):2090-2098.
PMID: 32833102
PMC: 7677272.
DOI: 10.1007/s10147-020-01770-2.
Health-related quality of life of exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study.
Huang Y, Li C, Chou Y, Ke H, Chen C
Int J Clin Pharm. 2019; 41(4):993-1003.
PMID: 31240550
DOI: 10.1007/s11096-019-00854-y.
Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative....
Ueno S, Kitagawa Y, Onozawa M, Hinotsu S, Akaza H, Mizokami A
Prostate Int. 2018; 6(1):7-11.
PMID: 29556483
PMC: 5857186.
DOI: 10.1016/j.prnil.2017.05.004.
The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset.
Cuypers M, Lamers R, Cornel E, van de Poll-Franse L, de Vries M, Kil P
Support Care Cancer. 2017; 26(4):1297-1304.
PMID: 29127529
PMC: 5847026.
DOI: 10.1007/s00520-017-3953-8.
Comparisons of oncological and functional outcomes among radical retropubic prostatectomy, high dose rate brachytherapy, cryoablation and high-intensity focused ultrasound for localized prostate cancer.
Chiang P, Liu Y
Springerplus. 2016; 5(1):1905.
PMID: 27867812
PMC: 5095104.
DOI: 10.1186/s40064-016-3584-4.
Proton therapy for early stage prostate cancer: is there a case?.
Chan T, Tan P, Tang J
Onco Targets Ther. 2016; 9:5577-86.
PMID: 27672328
PMC: 5024773.
DOI: 10.2147/OTT.S108559.
Psychosexual care in prostate cancer survivorship: a systematic review.
Goonewardene S, Persad R
Transl Androl Urol. 2016; 4(4):413-20.
PMID: 26816840
PMC: 4708596.
DOI: 10.3978/j.issn.2223-4683.2015.08.04.
Psychosocial and physical outcomes of in- and outpatient rehabilitation in prostate cancer patients treated with radical prostatectomy.
Rath H, Ullrich A, Otto U, Kerschgens C, Raida M, Hagen-Aukamp C
Support Care Cancer. 2016; 24(6):2717-26.
PMID: 26803833
DOI: 10.1007/s00520-016-3076-7.
Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population.
Alexander K, Chambers S, Spurdle A, Batra J, Lose F, OMara T
Qual Life Res. 2015; 24(9):2183-93.
PMID: 25724697
DOI: 10.1007/s11136-015-0950-6.
Prostate cancer in East Asia: evolving trend over the last decade.
Zhu Y, Wang H, Qu Y, Ye D
Asian J Androl. 2014; 17(1):48-57.
PMID: 25080928
PMC: 4291877.
DOI: 10.4103/1008-682X.132780.
Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments.
Schmidt S, Garin O, Pardo Y, Valderas J, Alonso J, Rebollo P
Qual Life Res. 2014; 23(8):2169-81.
PMID: 24748557
PMC: 4155169.
DOI: 10.1007/s11136-014-0678-8.
Are there specific health-related factors that can accentuate the risk of suicide among men with prostate cancer?.
Lehuluante A, Fransson P
Support Care Cancer. 2014; 22(6):1673-8.
PMID: 24515278
PMC: 4008778.
DOI: 10.1007/s00520-014-2150-2.
Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer.
Miwa S, Mizokami A, Konaka H, Ueno S, Kitagawa Y, Koh E
Prostate Int. 2013; 1(3):117-24.
PMID: 24223413
PMC: 3814119.
DOI: 10.12954/PI.13021.
Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.
Harden J, Sanda M, Wei J, Yarandi H, Hembroff L, Hardy J
Oncol Nurs Forum. 2013; 40(6):567-73.
PMID: 24161635
PMC: 3943427.
DOI: 10.1188/13.ONF.567-573.
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective.
Li C, Zeliadt S, Hall I, Smith J, Ekwueme D, Moinpour C
Support Care Cancer. 2013; 21(12):3461-9.
PMID: 23955026
PMC: 4535430.
DOI: 10.1007/s00520-013-1931-3.